Adoption of iCardiac’s Next Generation Cardiac Safety Solutions Continues to Accelerate.
(PRWEB) June 22, 2010 -- iCardiac Technologies, Inc., a provider of next generation cardiac core lab services, announced today that an additional three top 20 pharmaceutical companies have recently selected iCardiac as a preferred vendor. iCardiac will provide a full range of cardiac safety, ECG and blood pressure monitoring services and advanced analytics, including Highly Automated QT(sm) and Dynamic QT beat-to-beat(sm), as well as end-to-end global study logistics including ECG, Holter, and ABPM equipment deployment.
“We continue to see increased market demand for the next generation of cardiac safety solutions which provide more reliable results and improved resource efficiencies,” said Sasha Latypova, Executive Vice President. “The accelerated pace of adoption of our solutions is a testament to the superior scientific and business value, as well as the quality of service delivered by the dedicated and experienced team of cardiac safety professionals at iCardiac.”
In October 2005, the FDA introduced a new guidance for industry (ICH E14) requiring the evaluation of pro-arrhythmic potential of new drugs by measuring the QT segment of ECGs collected in clinical trials. The dissatisfaction among pharmaceutical developers with the poor precision, high rate of false positives/negatives and high cost of the “gold standard” manual or semi-automated QT measurements has lead to efforts toward providing more advanced cardiac safety analytics.
About iCardiac Technologies
iCardiac Technologies, Inc., provides drug development companies worldwide with the complete range of next generation cardiac safety core lab services.
Copyright©2010 Vocus, Inc.
All rights reserved